Difference between revisions of "Mocetinostat (MGCD-0103)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "2 PubMed]" to "2/ PubMed]") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Hodgkin lymphoma " to "[[Category:Classical Hodgkin lymphoma ") |
||
| Line 15: | Line 15: | ||
[[Category:HDAC inhibitors]] | [[Category:HDAC inhibitors]] | ||
| − | [[Category:Hodgkin lymphoma medications (investigational)]] | + | [[Category:Classical Hodgkin lymphoma medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 14:22, 9 June 2023
Mechanism of action
From the NCI Drug Dictionary: A rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity. Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur through the induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressors, down regulation of growth factors, oxidative stress, and autophagy, among others.
Preliminary data
Hodgkin lymphoma
- Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011 Dec;12(13):1222-8. Epub 2011 Oct 25. link to original article link to PMC article PubMed
Also known as
- Code name: MGCD0103